Related Experiment Videos
Syndecan-1 knockdown inhibits glioma cell proliferation and invasion by deregulating a c-src/FAK-associated signaling
Shuang Shi1,2, Dong Zhong1, Yao Xiao2
1Department of Neurosurgery, The 1st Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
Abstract:
Recent studies have shown that increased syndecan-1 (SDC1) expression in human glioma is associated with higher tumor grades and poor prognoses, but its oncogenic functions and the underlying molecular mechanisms remain unknown. Here, we examined SDC1 expression in datasets from The Cancer Genome Atlas and the National Center for Biotechnology Information Gene Expression Omnibus. Elevated SDC1 expression in glioma was closely associated with increases in tumor progression and shorter survival. We also examined SDC1 expression and evaluated the effects of stable SDC1 knockdown in glioma cell lines. SDC1 knockdown attenuated proliferation and invasion by glioma cells and markedly decreased PCNA and MMP-9 mRNA and protein expression. In a xenograft model, SDC1 knockdown suppressed the tumorigenic effects of U87 cells in vivo. SDC1 knockdown decreased phosphorylation of the c-src/FAK complex and its downstream signaling molecules, Erk, Akt and p38 MAPK. These results suggest that SDC1 may be a novel therapeutic target in the treatment of glioma.
Insights
Increased syndecan-1 (SDC1) expression drives glioma progression and poor outcomes. Silencing SDC1 inhibits tumor growth, invasion, and key signaling pathways, suggesting SDC1 as a potential therapeutic target for glioma.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Increased syndecan-1 (SDC1) expression correlates with higher glioma grades and poorer prognoses.
- The specific oncogenic roles and molecular mechanisms of SDC1 in glioma remain largely undefined.
Purpose of the Study:
- To investigate the functional role of SDC1 in glioma progression.
- To elucidate the molecular mechanisms underlying SDC1's oncogenic functions in glioma.
- To evaluate SDC1 as a potential therapeutic target for glioma treatment.
Main Methods:
- Analysis of SDC1 expression in The Cancer Genome Atlas and NCBI Gene Expression Omnibus datasets.
- In vitro studies involving stable SDC1 knockdown in glioma cell lines.
- In vivo evaluation using a U87 glioma xenograft model.
- Assessment of proliferation, invasion, PCNA, MMP-9, and signaling pathway phosphorylation (c-src/FAK, Erk, Akt, p38 MAPK).
Main Results:
- Elevated SDC1 expression in glioma is linked to tumor progression and reduced patient survival.
- SDC1 knockdown significantly attenuated glioma cell proliferation and invasion.
- SDC1 knockdown decreased PCNA and MMP-9 expression and suppressed tumor growth in vivo.
- SDC1 knockdown inhibited the phosphorylation of the c-src/FAK complex and downstream signaling molecules (Erk, Akt, p38 MAPK).
Conclusions:
- SDC1 plays a crucial role in promoting glioma cell proliferation, invasion, and tumorigenesis.
- SDC1 influences key signaling pathways involved in cancer progression.
- SDC1 represents a promising novel therapeutic target for glioma treatment.